Details of the Drug Combinations

General Information of This Drug (ID: DMREUQ6)

• Drug Name: Valsartan (DMREUQ6)
• Synonyms: valsartan; 137862-53-4; Diovan; Tareg; Provas; L-Valsartan; CGP 48933; Exforge; CGP-48933; (S)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid; UNII-80M03YXJ7I; N-(p-(o-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine; CHEMBL1069; 80M03YXJ7I; CHEBI:9927; C24H29N5O3; (2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid; N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine; 137863-60-6; AK-58790; Kalpress; Miten; Nisis; Diovan; Vals; Valsarran; Walsartan; Aventis brand of valsartan; CEPA brand of valsartan; Esteve brand of valsartan; Lacer brand of valsartan; Novartis brand of valsartan; Sanol brand of valsartan; Schwarz brand of valsartan; Diovan (TN); Diovan, Valsartan; Valsartan [USAN:INN]; Valtan (TN); Valzaar (TN); Valsartan (JAN/USAN/INN); N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine; N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine; N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-L-valine; L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-(9CI); (S)-N-valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine; (s)-2-(n-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)-3-methylbutanoic acid; [3H]valsartan

Indication

Chronic heart failure; ICD 11: BD1Z; Status: Approved [1]; Hypertension; ICD 11: BA00-BA04; Status: Approved [2]; Coronavirus Disease 2019 (COVID-19); ICD 11: 1D6Y; Status: Phase 3 [3]; Nephropathy; ICD 11: GC2Z; Status: Investigative [1]

• Therapeutic Class: Antihypertensive Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

24 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Aliskiren + Valsartan	DCS7PNS	Aliskiren	Hypertension	[4]
Aliskiren + Valsartan	DC0NJ59	Aliskiren	Hypertension	[4]
Aliskiren + Valsartan	DCMA0K9	Aliskiren	Acute coronary syndrome	[5]
Amlodipine + Valsartan	DC55AFZ	Amlodipine	Hypertension	[6]
Amlodipine + Valsartan	DCYIBJG	Amlodipine	Hypertension; Hypertrophy, Left Ventricular	[7]
Bunazosin + Valsartan	DC0V8XX	Bunazosin	High Blood Pressure	[8]
Dapagliflozin + Valsartan	DC8IHVT	Dapagliflozin	Type 2 Diabetes Mellitus	[9]
Doxazosin + Valsartan	DC7V9BL	Doxazosin	High Blood Pressure	[8]
Ezetimibe + Valsartan	DC1K153	Ezetimibe	Hypertension	[10]
Imiglitazar + Valsartan	DCBRQEN	Imiglitazar	T2DM	[11]
Pravastatin + Valsartan	DC4W0ED	Pravastatin	Hypertension	[10]
Simvastatin + Valsartan	DCFR2FF	Simvastatin	Hypertension	[10]
Valsartan + Losartan	DC0I0XI	Losartan	Hypertension	[12]
Valsartan + Enalapril	DC2DS8Q	Enalapril	Hypertension	[13]
Valsartan + Probucol	DC2V7NE	Probucol	Type 2 Diabetes Mellitus	[14]
Valsartan + Hydrochlorothiazide	DC4JNLS	Hydrochlorothiazide	Hypertension	[15]
Valsartan + Entresto	DCGELAZ	Entresto	Systolic Hypertension	[16]
Valsartan + Probucol	DCLFY1P	Probucol	Glomerulonephritis	[17]
Valsartan + Levocetirizine	DC7YLAY	Levocetirizine	Diabetic Nephropathies	[18]
Valsartan + Empagliflozin	DC650YQ	Empagliflozin	Diabetic Nephropathies	[18]
Amlodipine + Valsartan	DCGCOKA	Amlodipine	Hypertension	[19]
Valsartan + Atenolol	DC82630	Atenolol	Hypertension	[20]
Valsartan + Rosuvastatin	DCS2118	Rosuvastatin	Hypertension,	[21]
Valsartan + Hydroxychloroquine	DC5NZ4M	Hydroxychloroquine	Primary IgA Nephropathy	[22]

References

• [1] Valsartan FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3937).
• [3] Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease
• [4] ClinicalTrials.gov (NCT00386607) A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.
• [5] ClinicalTrials.gov (NCT00409578) Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome. U.S. National Institutes of Health.
• [6] ClinicalTrials.gov (NCT00523549) The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction
• [7] ClinicalTrials.gov (NCT00446563) Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy
• [8] ClinicalTrials.gov (NCT00130156) Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension
• [9] ClinicalTrials.gov (NCT00839683) Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects
• [10] ClinicalTrials.gov (NCT00738972) Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients (MK0653A-168)
• [11] ClinicalTrials.gov (NCT05681273) Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.
• [12] ClinicalTrials.gov (NCT00732966) Ocsaar and CYP2C9 Ploymorphism, Is There a Connection Between Pharmacokinetics, Pharmacodynamics and Pharmacogenetics?
• [13] ClinicalTrials.gov (NCT00446511) Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension
• [14] ClinicalTrials.gov (NCT00655330) Probucol Combined With Valsartan in Reducing Proteinuria in Diabetes Nephropathy
• [15] ClinicalTrials.gov (NCT00171054) Efficacy and Safety of Valsartan Versus Amlodipine in Postmenopausal Women With Hypertension
• [16] ClinicalTrials.gov (NCT01281306) An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension
• [17] ClinicalTrials.gov (NCT00426348) A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy
• [18] ClinicalTrials.gov (NCT05638880) Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney Disease
• [19] ClinicalTrials.gov (NCT01365481) Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age
• [20] ClinicalTrials.gov (NCT00396656) Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients
• [21] ClinicalTrials.gov (NCT01918332) Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia
• [22] ClinicalTrials.gov (NCT02765594) Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy